4-氯-5-氨磺酰邻氨基苯甲酸

更新时间：2025-08-23 11:54:54

4-氯-5-氨磺酰邻氨基苯甲酸结构式	常用名	4-氯-5-氨磺酰邻氨基苯甲酸	英文名	4-Chloro-5-sulfamoylanthranilic Acid
	CAS号	3086-91-7	分子量	250.65900
	密度	1.726g/cm3	沸点	549.2ºC at 760mmHg
	分子式	C₇H₇ClN₂O₄S	熔点	267°C (dec.) (lit.)
	MSDS	N/A	闪点	286ºC
	符号	GHS07	信号词	Warning

中文名	4-氯-5-氨磺酰邻氨基苯甲酸
英文名	2-amino-4-chloro-5-sulfamoylbenzoic acid
英文别名	更多

密度	1.726g/cm3
沸点	549.2ºC at 760mmHg
熔点	267°C (dec.) (lit.)
分子式	C₇H₇ClN₂O₄S
分子量	250.65900
闪点	286ºC
精确质量	249.98200
PSA	131.86000
LogP	2.63010
InChIKey	QQLJBZFXGDHSRU-UHFFFAOYSA-N
SMILES	Nc1cc(Cl)c(S(N)(=O)=O)cc1C(=O)O
外观性状	固体
折射率	1.665
储存条件	室温

符号	GHS07
信号词	Warning
危害声明	H315-H319-H335
警示性声明	P305 + P351 + P338
危害码 (欧洲)	N
危险品运输编码	NONH for all modes of transport
海关编码	2935009090

呋噻米

54-31-9

~51%

4-氯-5-氨磺酰邻氨基苯甲酸

3086-91-7

文献：NITROMED, INC. Patent: WO2006/55542 A2, 2006 ; Location in patent: Page/Page column 69-70 ; WO 2006/055542 A2

2-(乙酰基氨基)-5-(氨基...

17560-54-2

4-氯-5-氨磺酰邻氨基苯甲酸

3086-91-7

文献：Journal of the American Chemical Society, , vol. 81, p. 5508 Journal of the American Chemical Society, , vol. 82, p. 2731,2733,2734 US2952680 , ; US2910488 , ;

N-(5-氯-2-甲基-4-磺...

17560-53-1

4-氯-5-氨磺酰邻氨基苯甲酸

3086-91-7

文献：Journal of the American Chemical Society, , vol. 81, p. 5508 Journal of the American Chemical Society, , vol. 82, p. 2731,2733,2734 US2952680 , ; US2910488 , ;

5-氯-2-甲基乙酰苯胺

5900-55-0

4-氯-5-氨磺酰邻氨基苯甲酸

3086-91-7

文献：Journal of the American Chemical Society, , vol. 81, p. 5508 Journal of the American Chemical Society, , vol. 82, p. 2731,2733,2734

甲醇

67-56-1

呋噻米

54-31-9

~29%

4-chloro-2-[(2,...

1351169-05-5

4-氯-5-氨磺酰邻氨基苯甲酸

3086-91-7

文献：Tetrahedron, , vol. 67, # 49 p. 9518 - 9521

4-氯-5-氨磺酰邻氨基苯甲酸上游产品 5
CAS号54-31-9 呋噻米 CAS号17560-54-2 2-(乙酰基氨基)-5-(氨基... CAS号17560-53-1 N-(5-氯-2-甲基-4-磺... CAS号5900-55-0 5-氯-2-甲基乙酰苯胺
CAS号67-56-1 甲醇
4-氯-5-氨磺酰邻氨基苯甲酸下游产品 1
CAS号34121-17-0 2-amino-4-chlor...

海关编码	2935009090
中文概述	2935009090 其他磺（酰）胺. 增值税率:17.0% 退税率:9.0% 监管条件:无最惠国关税:6.5% 普通关税:35.0%
申报要素	品名, 成分含量, 用途
Summary	2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0%

The use of HPLC to elucidate the metabolism and urinary excretion of furosemide and its metabolic products.

Acta Pharmacol. Toxicol. (Copenh.) 49(3) , 223-9, (1981)

Three principles for the use of HPLC with spectrophotometric detection to determine the concentration of furosemide and of 4-chloro-5-sulfamoyl anthranilic acid (CSA) were studied. A reversed phase mi...

The binding of furosemide to serum proteins in elderly patients: displacing effect of phenprocoumon.

Acta Pharmacol. Toxicol. (Copenh.) 47(3) , 202-7, (1980)

The percentual binding of furosemide (5 micrograms/ml) was slightly but significantly lower in serum from elderly patients than in serum from normal blood donors (96.5 +/- 0.7 versus 97.9 +/- 0.3). A ...

Furosemide accelerates gentamicin accumulation in cultured renal cells (LLC-PK1 cells).

Nephron 53(2) , 138-41, (1989)

Furosemide is known to potentiate gentamicin nephrotoxicity. The mechanism of potentiation is unclear. In our previous studies, we demonstrated that furosemide enhanced gentamicin accumulation in rabb...

4-Chloro-5-sulfamoylanthranilic acid

2-AMINO-5-AMINOSULFONYL-4-CHLOROBENZOIC ACID

4-chloro-5-sulphamoyl anthranilic acid

Desfurylmethylfurosemide

Saluamine

2-amino-4-chloro-5-sulfamoyl-benzoic acid

Furosemide Related Compound B

EINECS 221-408-7

4-chloro-5-sulfamoyl-anthranilic acid

4-Chloro-5-sulfanilanthranilic acid